Systems Medicine for Precise Targeting of Glioblastoma Systems Medicine Against Glioblastoma.
Jie ZengXiao Xue ZengPublished in: Molecular biotechnology (2023)
Glioblastoma (GBM) is a malignant cancer that is fatal even after standard therapy and the effects of current available therapeutics are not promising due its complex and evolving epigenetic and genetic profile. The mysteries that lead to GBM intratumoral heterogeneity and subtype transitions are not entirely clear. Systems medicine is an approach to view the patient in a whole picture integrating systems biology and synthetic biology along with computational techniques. Since the GBM oncogenesis involves genetic mutations, various therapies including gene therapeutics based on CRISPR-Cas technique, MicroRNAs, and implanted synthetic cells endowed with synthetic circuits against GBM with neural stem cells and mesenchymal stem cells acting as potential vehicles carrying therapeutics via the intranasal route, avoiding the risks of invasive methods in order to reach the GBM cells in the brain are discussed and proposed in this review. Systems medicine approach is a rather novel strategy, and since the GBM of a patient is complex and unique, thus to devise an individualized treatment strategy to tailor personalized multimodal treatments for the individual patient taking into account the phenotype of the GBM, the unique body health profile of the patient and individual responses according to the systems medicine concept might show potential to achieve optimum effects.
Keyphrases
- case report
- mesenchymal stem cells
- crispr cas
- induced apoptosis
- genome wide
- public health
- small molecule
- human health
- cell cycle arrest
- neural stem cells
- gene expression
- dna methylation
- copy number
- social media
- mental health
- umbilical cord
- signaling pathway
- stem cells
- cell death
- health information
- climate change
- chronic pain
- pi k akt
- blood brain barrier